---
document_datetime: 2023-09-21 18:19:45
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-acino-pharma-gmbh-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-acino-pharma-gmbh-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3703441
conversion_datetime: 2025-12-27 15:52:46.920723
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Clopidogrel Acino Pharma GmbH

Procedural steps taken and scientific information after the authorisation

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3 Summary longer   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|-------------------------------------------------|
| IB/0007 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH To update section 4.2 \"Posology and method of administration\" and 5.1 \"Pharmacodynamic properties\" of clopidogrel SPC to include new paediatric information available for clopidogrel. Minor linguistic changes have been introduced in the product information, to bring the product in line with the reference product. | 22/07/2011                          | n/a no                                      | SPC                                             |
| IB/0006 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional                                                                                                                                                                                                                                                                                                                                                         | 29/04/2011 product                  | n/a                                         | SPC, Annex II, PL                               |

<!-- image -->

<!-- image -->

7 Westferry Circus

●

Canary Wharf

●

London E14 4HB

●

United Kingdom

Telephone

+44 (0)20 7418 8400 Facsimile +44 (0) 20 7418 8613

E-mail

info@ema.europa.eu Website www.ema.europa.eu

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary    |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------|
|         | data are submitted by the MAH To update the Summary of Product Characteristics (SmPC) and Package Leaflet to update sections 4.2 \"Posology and method of administration\", 4.4 \"Special warnings and precautions for use\", 4.5 \"Interaction with other medicinal products and other forms of interaction\" and 5.2 \"Pharmacokinetic properties\" of clopidogrel/acetylsalicylic acid (ASA) SPC to include new information on the variability of response to clopidogrel due to either genetic variations of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitor (PPI). In addition, section 4.8 has been amended with minor details on the CURE study. Additional changes have been added to the SmPC and Package Leaflet in order to bring it in line with the revised QRD template (version 7.3) In addition, the deletion of DDPS number version and date was introduced in Annex IIB as requested by the EMA with the procedural announcement in October and November 2010. Minor linguistic changes have been introduced in the product information, to bring the | product                             | no                                          | longer                           | authorised |
| IB/0005 | product in line with the reference product. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH Amendments are introduced into the product information, in accordance with the respective amendments to the reference Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 06/08/2010                          | n/a                                         | SPC, Labelling, PL               |            |

<div style=\"page-break-after: always\"></div>

| No       | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                         |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------|
|          | product, to include information on the clopidogrel metabolism pathway, the role of CYP2C19 genetic polymorphism on clopidogrel variability of response and the potential interaction between clopidogrel and CYP2C19 inhibitors including some proton pump inhibitors. Additionally, some minor amendments were made to up-date the product information with regard to QRD and to clear out the differences in wording in comparison to the reference product, the marketing authorisation number and date were added and the list of Local Representatives was deleted. |                                     |                                             | longer                           | authorised                                                                                                      |
| A20/0004 | Pursuant to Article 20 of Regulation (EC) No 726/2004 of 31 March 2004, the European Commission requested on 18 March 2010, the opinion of the CHMP on measures necessary to ensure the quality of the above mentioned medicinal product further to GMP deficiencies of the API manufacturing site Glochem Industries Ltd. (Unit II). Article 20 Review                                                                                                                                                                                                                  | 18/03/2010                          | 29/03/2010 no                               |                                  | Please refer to the Assessment Report: Clopidogrel Acino Pharma GmbH-H-1175-A20-04-Assessment Report-Article 20 |
| II/0002  | To introduce a new active substance manufacturer. Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 21/01/2010 product                  | 10/02/2010                                  |                                  |                                                                                                                 |
| II/0003  | To register a revised version of the ASMF for clopidogrel besilate from the existing active substance manufacturer, introducing changes in the manufacturing process of the active substance. Quality changes Medicinal                                                                                                                                                                                                                                                                                                                                                  | 21/01/2010                          | 04/02/2010                                  |                                  |                                                                                                                 |
| IA/0001  | 07_a_Replacement/add. of manufacturing site: Secondary packaging site,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/10/2009                          | n/a                                         |                                  |                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| No   | Scope                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------|--------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
|      | 07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms |                                     |                                             |                                  |           |

<!-- image -->